




Searching News Database: generalized anxiety disorder
HSMN NewsFeed - 10 Feb 2020
Biohaven's Troriluzole Study For Generalized Anxiety Disorder (GAD) Misses Primary Endpoint
Biohaven's Troriluzole Study For Generalized Anxiety Disorder (GAD) Misses Primary Endpoint
HSMN NewsFeed - 28 May 2018
Luye Pharma Acquires AstraZeneca's Signature Products Seroquel and Seroquel XR
Luye Pharma Acquires AstraZeneca's Signature Products Seroquel and Seroquel XR
HSMN NewsFeed - 19 May 2014
Nektar Appoints Ivan Gergel, M.D. as Senior Vice President, Drug Development & Chief Medical Officer
Nektar Appoints Ivan Gergel, M.D. as Senior Vice President, Drug Development & Chief Medical Officer
HSMN NewsFeed - 30 Nov 2009
FDA Approves Cymbalta(R) for Maintenance Treatment of Generalized Anxiety Disorder
FDA Approves Cymbalta(R) for Maintenance Treatment of Generalized Anxiety Disorder
HSMN NewsFeed - 11 Sep 2009
New Data Show Patients With Chronic Low Back Pain Maintained Pain Reduction on Cymbalta(R)
New Data Show Patients With Chronic Low Back Pain Maintained Pain Reduction on Cymbalta(R)
HSMN NewsFeed - 10 Dec 2008
Study Showed New Episodes of Depression Delayed in People Taking Cymbalta(R)
Study Showed New Episodes of Depression Delayed in People Taking Cymbalta(R)
HSMN NewsFeed - 28 Nov 2008
Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain
Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain
HSMN NewsFeed - 17 Nov 2008
Mylan Receives Tentative FDA Approval for the Generic Version of the Antidepressant Effexor XR(R)
Mylan Receives Tentative FDA Approval for the Generic Version of the Antidepressant Effexor XR(R)
HSMN NewsFeed - 26 Sep 2008
Indevus Announces Agreement With Teva to Develop Pagoclone for the Treatment of Stuttering
Indevus Announces Agreement With Teva to Develop Pagoclone for the Treatment of Stuttering
HSMN NewsFeed - 8 Sep 2008
MediciNova to Present At Merriman Curhan Ford's 5th Annual Investor Summit 2008
MediciNova to Present At Merriman Curhan Ford's 5th Annual Investor Summit 2008
HSMN NewsFeed - 25 Aug 2008
Patients Taking Cymbalta(R) Experienced Reduced Chronic Low Back Pain in New Study
Patients Taking Cymbalta(R) Experienced Reduced Chronic Low Back Pain in New Study
HSMN NewsFeed - 22 Aug 2008
Cymbalta Receives European Approval for the Treatment of Generalised Anxiety Disorder
Cymbalta Receives European Approval for the Treatment of Generalised Anxiety Disorder
HSMN NewsFeed - 27 Jun 2008
European CHMP Issues Positive Opinion on Cymbalta for the Treatment of Generalised Anxiety Disorder
European CHMP Issues Positive Opinion on Cymbalta for the Treatment of Generalised Anxiety Disorder
HSMN NewsFeed - 13 Jun 2008
Patients Taking Cymbalta(R) Reported Reduced Pain Severity of Osteoarthritis of the Knee in New Study
Patients Taking Cymbalta(R) Reported Reduced Pain Severity of Osteoarthritis of the Knee in New Study
HSMN NewsFeed - 27 Feb 2008
Forest Laboratories, Inc. Announces Amendment to Bystolic(TM) (nebivolol) Agreement
Forest Laboratories, Inc. Announces Amendment to Bystolic(TM) (nebivolol) Agreement
HSMN NewsFeed - 1 Feb 2008
MediciNova's MN-166 Reduces Persistent Black Hole Formation in Multiple Sclerosis Patients
MediciNova's MN-166 Reduces Persistent Black Hole Formation in Multiple Sclerosis Patients
HSMN NewsFeed - 18 Dec 2007
Bystolic(TM), a Novel Beta Blocker, is Now Approved by the FDA for the Treatment of Hypertension
Bystolic(TM), a Novel Beta Blocker, is Now Approved by the FDA for the Treatment of Hypertension
HSMN NewsFeed - 2 Dec 2007
FDA Issues Approvable Letter for Nebivolol for the Treatment of Hypertension
FDA Issues Approvable Letter for Nebivolol for the Treatment of Hypertension
HSMN NewsFeed - 30 Nov 2007
FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
HSMN NewsFeed - 17 Sep 2007
Microbia and Forest Laboratories Announce Linaclotide Co-Development and Co-Marketing Collaboration
Microbia and Forest Laboratories Announce Linaclotide Co-Development and Co-Marketing Collaboration
HSMN NewsFeed - 5 Sep 2007
Forest Laboratories Announces Federal Appeals Court Upholds Lexapro(R) Patent Decision
Forest Laboratories Announces Federal Appeals Court Upholds Lexapro(R) Patent Decision
HSMN NewsFeed - 21 Aug 2007
New Data Suggest Cymbalta(R) Reduced Pain in Fibromyalgia Patients With and Without Depression
New Data Suggest Cymbalta(R) Reduced Pain in Fibromyalgia Patients With and Without Depression
HSMN NewsFeed - 21 Aug 2007
Daiichi Sankyo and Forest Laboratories Sign Letter of Intent for Co-Promotion of AZOR(TM)
Daiichi Sankyo and Forest Laboratories Sign Letter of Intent for Co-Promotion of AZOR(TM)
HSMN NewsFeed - 6 Aug 2007
Pfizer Says Growth in Phase II Portfolio Supports Goal of Tripling Phase III Portfolio by 2009
Pfizer Says Growth in Phase II Portfolio Supports Goal of Tripling Phase III Portfolio by 2009
HSMN NewsFeed - 27 Jul 2007
Sepracor Submits LUNIVIA(R) (LUNESTA(R) in U.S.) Marketing Authorization Application (MAA) for Europe
Sepracor Submits LUNIVIA(R) (LUNESTA(R) in U.S.) Marketing Authorization Application (MAA) for Europe
HSMN NewsFeed - 10 Jul 2007
Noven to Acquire JDS Pharmaceuticals, Expanding Business Model & Broadening Product Pipeline
Noven to Acquire JDS Pharmaceuticals, Expanding Business Model & Broadening Product Pipeline
HSMN NewsFeed - 21 May 2007
Data Suggest Cymbalta(R) Improved Functioning in Patients With Generalized Anxiety Disorder
Data Suggest Cymbalta(R) Improved Functioning in Patients With Generalized Anxiety Disorder
HSMN NewsFeed - 3 May 2007
Data Suggest Cymbalta(R) Reduced Severity of Night Pain in Patients with Diabetic Nerve Pain
Data Suggest Cymbalta(R) Reduced Severity of Night Pain in Patients with Diabetic Nerve Pain
HSMN NewsFeed - 1 May 2007
Response Submitted to FDA Approvable Letter for Hypertension Compound Nebivolol
Response Submitted to FDA Approvable Letter for Hypertension Compound Nebivolol
HSMN NewsFeed - 27 Mar 2007
MediciNova Announces Positive Clinical Results From MN-166 Phase II Multiple Sclerosis Trial
MediciNova Announces Positive Clinical Results From MN-166 Phase II Multiple Sclerosis Trial
HSMN NewsFeed - 14 Dec 2006
Cerexa to Be Acquired by Forest Laboratories for $480 Million Plus Potential $100 Million Milestone Payment
Cerexa to Be Acquired by Forest Laboratories for $480 Million Plus Potential $100 Million Milestone Payment
HSMN NewsFeed - 1 Nov 2006
MediciNova Announces the Acquisition of Two Novel Antithrombotic Agents from Meiji Seika Kaisha, Ltd.
MediciNova Announces the Acquisition of Two Novel Antithrombotic Agents from Meiji Seika Kaisha, Ltd.
HSMN NewsFeed - 23 Oct 2006
U.S. Food and Drug Administration Issues Non-Approvable Letter for Faropenem
U.S. Food and Drug Administration Issues Non-Approvable Letter for Faropenem
HSMN NewsFeed - 30 Jun 2006
EPIX Pharmaceuticals Files Appeal with FDA Regarding Vasovist(TM) Approvable Letters
EPIX Pharmaceuticals Files Appeal with FDA Regarding Vasovist(TM) Approvable Letters
HSMN NewsFeed - 26 Jun 2006
Cephalon Announces Results from GABITRIL(R) Clinical Program in Generalized Anxiety Disorder
Cephalon Announces Results from GABITRIL(R) Clinical Program in Generalized Anxiety Disorder
HSMN NewsFeed - 9 May 2006
Lilly Submits Cymbalta(R) Supplemental New Drug Application for Generalized Anxiety Disorder
Lilly Submits Cymbalta(R) Supplemental New Drug Application for Generalized Anxiety Disorder
Additional items found! 84

Members Archive contains
84 additional stories matching:
generalized anxiety disorder
(Password required)
generalized anxiety disorder
(Password required)